Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Bengaluru"

170 News Found

Sparsh hospital opens multi-organ transplant centre in Bengaluru
Hospitals | January 29, 2022

Sparsh hospital opens multi-organ transplant centre in Bengaluru

The new centre will comprise a team of 50 highly experienced specialists


Stelis commissions vaccine facility in Bengaluru
News | December 21, 2021

Stelis commissions vaccine facility in Bengaluru

The company has started manufacturing the Sputnik Light vaccine


Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits
News | February 23, 2021

Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits

Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.


Zota Health Care expands Davaindia network to 1,530 stores
Healthcare | March 20, 2025

Zota Health Care expands Davaindia network to 1,530 stores

The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru


Syngene acquires first US biologics facility for $36.5 million
News | March 11, 2025

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million


Biocon Academy conducts 9th Graduation Day
News | March 04, 2025

Biocon Academy conducts 9th Graduation Day

Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations


Biocon Foundation marks 20 years of transforming lives
News | February 28, 2025

Biocon Foundation marks 20 years of transforming lives

Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives


Briefs: Syngene International and Cipla
Drug Approval | February 23, 2025

Briefs: Syngene International and Cipla

Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’


Briefs: Caplin Point Laboratories, Hikal and Cipla
Drug Approval | February 10, 2025

Briefs: Caplin Point Laboratories, Hikal and Cipla

Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru


Strides reports 14.6% growth in Q3 FY25 revenue
News | January 31, 2025

Strides reports 14.6% growth in Q3 FY25 revenue

EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore